Table.

Laboratory Findings at Initial Examination.

Blood cell couunt			Immunologocal marker			Respiratory function test
WBC	4,150	/μL	IgG	1,196	mg/dL	VC	3.34	L	(73.2%)
Neut.	56.2	%	IgG4	53	mg/dL	FVC	3.48	L	(77.9%)
Lymp.	27.7	%	IgE	9,556	IU/mL	FEV1	2.75	L	(71.1%)
Eosi.	5.3	%	ANA	40		FEV1/FVC	79.0	%
Hb	14.0	g/dL	Homo	40		%DLCO	66.1%
Plt	14.9	×104/μL	RF	3		%DLCO/VA	77.9%
Biochemistory			Anti CCP	0.6
Alb	4.3	g/dL	Anti ds-DNA	(-)		Bronchoalveolar lavage
AST	49	IU/L	Anti SS-A	(-)		Site	Rt B5
ALT	54	IU/L	Anti SS-B	(-)		Collection rate	59	%
LDH	289	IU/L	Anti ARS	(-)		Total cell count	5.1	×105/mL
CK	246	IU/L	Anti Scl-70	(-)		Macrophages	80	%
Cr	0.73	mg/dL	Anti U1-RNP	(-)		Lymphocytes	14	%
CRP	0.35	mg/dL	Anti Sm	(-)		Neutrophils	3	%
KL-6	881	U/mL	Anti MPO-ANCA	(-)		Eosinophils	3	%
Sp-D	221	ng/dL	Anti PR3-ANCA	(-)		CD4/8 ratio	2.8

WBC: white blood cell, Hb: hemoglobin, Plt: platelet, Alb: albumin, AST: aspartate transaminase, ALT: alanine aminotransferase, LDH; lactate dehydrogenase, CK: creatine kinase, Cr: creatinine, CRP: C-reactive protein, KL-6: Krebs von den Lungen-6, Sp-D: surfactant protein-D, IgG: immunoglobulin G, IgE: immunoglobulin E, ANA: antinuclear antibody, CCP: cyclic citrullinated peptide, MPO-ANCA: myeloperoxidase anti-neutrophil cytoplasmic antibody, PR3-ANCA: proteinase-anti-neutrophil cytoplasmic antibody, FVC: forced vital capacity, FEV: forced expiratory volume